New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
16:15 EDTPTCT, ARUN, GME, ARO, HPQOn The Fly: Closing Wrap
Stocks on Wall Street opened in quiet fashion, though with an upward bias, and proceeded to trade that way throughout the session. The averages drifted higher in a broad based move that saw each of the major averages tack on gains of at least 0.3%. The volume was light, as was to be expected prior to a holiday weekend, and there was little volatility as the market moved in a narrow range once it found its level. Ending the week on a high note, the benchmark S&P 500 managed to close above 1,900 for the first time. ECONOMIC EVENTS: In the U.S., new home sales rose 6.4% in April to a rate of 433K. The percentage increase trailed expectations, but the rate was higher than expected due to upward revisions to last months figures. COMPANY NEWS: Shares of Hewlett-Packard (HPQ) rose $2.00, or 6.1%, to $33.72 after the computer and printer making giant reported second quarter adjusted earnings per share that matched estimates and announced additional job cuts. Following the report, Citigroup said it sees "meaningful upside" to the stock and believes HP's cost savings are underappreciated. After HP's report of roughly in-line results and more layoffs, Wells Fargo noted that HP said it was more confident in its growth outlook. The firm thinks the layoffs may reflect newly discovered cost cutting opportunities, rather than end market pressures, and kept an Outperform rating on the shares. MAJOR MOVERS: Among the notable gainers was PTC Therapeutics (PTCT), which surged $4.71, or 30.74%, to $20.03 after the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion regarding the company's application for a conditional marketing authorization of Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy. Also higher was video game retailer GameStop (GME), which rose $1.55, or 4.2%, to $38.43 after the company reported better than expected first quarter profits and backed its fiscal 2014 guidance. Among the noteworthy losers following their earnings reports were apparel retailer Aeropostale (ARO), which fell $1.09, or 24.12%, to $3.43, and network solutions provider Aruba Networks (ARUN), which slid $2.17, or 10.82%, to $17.89. INDEXES: The Dow was up 63.19, or 0.38%, to 16,606.27, the Nasdaq was up 31.47, or 0.76%, to 4,185.81, and the S&P 500 was up 8.04, or 0.42%, to 1,900.53.
News For HPQ;GME;PTCT;ARO;ARUN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
November 23, 2015
08:35 EDTGMEGameStop says Q3 results at low end of guidance range
Subscribe for More Information
08:34 EDTGMEGameStop sees Q4 EPS $2.12-$2.32, consensus $2.37
Sees Q4 SSS down 1% to up 6%.
08:34 EDTGMEGameStop reiterates FY EPS view $3.66-$3.86, consensus $3.91
Subscribe for More Information
08:33 EDTGMEGameStop reports Q3 adjusted EPS 54c, consensus 59c
Reports Q3 revenue $2.02B, consensus $2.14B. Including one-time charges, EPS was 53c. Reports Q3 SSS down 1.1%, with SSS down 1.7% in the U.S. and up 0.3% internationally. Foreign currency exchange rate changes negatively impacted sales by approximately $100 million and earnings per share by $0.02. In the new video game segments, new hardware sales declined 20.4%, while new software sales decreased 9.3% due to the tough overlap of Destiny and Super Smash Bros. in Q3 2014.
08:22 EDTHPQHP Inc. volatility elevated into Q4 and outlook
HP Inc. November weekly call option implied volatility is at 52, December is at 34, January is at 31 compared to its 2-week range of 18 to 41, suggesting large near term price movement into the expected release of Q4 results on November 24.
07:44 EDTPTCTPTC Therapeutics should be owned ahead of BioMarin panel, says Oppenheimer
Subscribe for More Information
07:27 EDTHPQHP Inc. upgraded to Buy from Hold at Maxim
06:30 EDTGMEGameStop sees challenge around growing number of digital shoppers, WSJ says
Subscribe for More Information
06:09 EDTHPQHP Inc. adds Titan to Engineered by HP Program
HP Inc. announced the expansion of its Engineered by HP program, collaborating with the world's fifth largest watchmaker, Titan, to infuse technology seamlessly into the way consumers live, providing them with smart accessories that are productive and responsive, but not intrusive.
November 20, 2015
13:26 EDTPTCTOn The Fly: Top stock stories at midday
Stocks began the session sharply higher and have remained there since the open. The move higher has come despite a barren economic calendar and amid headlines coming out of Mali regarding a new terrorist event that took place there. The equity market is working on its fourth higher close in the past five sessions, while oil prices continue struggling to stay above $40 per barrel. ECONOMIC EVENTS: In the U.S., no major economic data was released. COMPANY NEWS: Shares of Nike (NKE) advanced nearly 5% after the Dow member announced a two-for-one stock split, a $12B stock repurchase program and plans to boost its dividend... BioMarin (BMRN) shares were down 4% near noon, but that was well off their worst levels of the day, after the FDA posted briefing materials ahead of next weeks advisory committee meeting to review the New Drug Application for Kyndrisa for the potential treatment of Duchenne muscular dystrophy amendable to exon 51 skipping. Sarepta (SRPT), which is at work on a competing drug, eteplirsen, that has its own committee review scheduled for January, rose 31% and another player in the DMD space, PTC Therapeutics (PTCT), fell 7.5%. MAJOR MOVERS: Among the notable gainers was Abercrombie & Fitch (ANF), which rallied 21% after the company reported better than expected quarterly earnings. Also higher was Cabela's (CAB), which gained 10% after Bloomberg reported that the company was receiving takeover interest. In addition, Foot Locker (FL) was up 5% after reporting Q3 earnings and guiding for Q4. Among the noteworthy losers was Nimble Storage (NMBL), which fell 50% after its stock was downgraded by no fewer than 11 analysts following its quarterly report. Also lower was Mentor Graphics (MENT), which lost 32% after its shares were downgraded by no fewer than five analysts. INDEXES: In early afternoon trading, the Dow was up 101.65, or 0.57%, to 17,834.40, the Nasdaq was up 32.02, or 0.63%, to 5,105.66, and the S&P 500 was up 10.09, or 0.48%, to 2,091.33.
10:49 EDTAROAbercrombie & Fitch soars after reporting upbeat Q3 earnings
Abercrombie & Fitch (ANF) shares jumped in morning trading after the company reported better than expected quarterly earnings. WHAT'S NEW: Before the market open, Abercrombie & Fitch reported third quarter adjusted earnings per share of 48c on revenue of $878.6M. The consensus was for EPS of 22c on revenue of $864.65M. The company said that the adjusted EPS figure included year-over-year adverse effects from changes in foreign currency exchange rates amounting to roughly 13c. Commenting on the earnings, executive chairman Arthur Martinez said that the company's results "exceeded" expectations and "provide the strongest validation yet" that the retailer's initiatives are working. WHAT'S NOTABLE: On its Q3 earnings conference call, Abercrombie said that it is eyeing expansion outside of the U.S., aiming to roll out multiple new capabilities in the U.K. The company added that it saw growth in China in the past quarter and plans to add mobile enhancements in China in 2016. STREET RESEARCH: A day before Abercrombie's Q3 earnings release, Susquehanna analyst Thomas Filandro said that the retailer was "well positioned" for the holiday season, though weather and international unrest may lead to a higher degree of near-term uncertainty. Filandro said that his firm sees improved holiday performance as Abercrombie shifts focus on an improved in-store experience, growing U.S. outlets, closing underperforming stores, and evolving its merchandise assortment. The analyst reiterated a Positive rating and a $26 price target on the company's stock. After the retailer reported earnings, KeyBanc analyst Edward Yruma maintained an Overweight rating on Abercrombie's shares, saying that the company's better than expected quarter was "particularly impressive" in light of the recent weakness in the retail sector. Yruma said that the company's new brand initiatives are taking hold and that greater expense control and reduced promotional activity are improving the well-being of the business. PRICE ACTION: In morning trading, Abercrombie & Fitch rallied over 18% to $23.00. OTHERS TO WATCH: American Eagle Outfitters (AEO) was up just under 3%, Aeropostale (ARO) gained 0.75%, Tilly's (TLYS) rallied 3.4%, Urban Outfitters (URBN) jumped more than 4%, Buckle (BKE) was up just under 1%, and Express (EXPR) fell fractionally in morning trading.
08:31 EDTGMEGameStop volatility elevated into Q3 and outlook
Subscribe for More Information
08:05 EDTPTCTBioMarin drops after FDA posts review of DMD drug drisapersen
Shares of BioMarin are down 7% to $96.01 after the FDA posted a review of the company's Duchenne muscular dystrophy treatment drisapersen ahead of Tuesday's panel vote. Sarepta Therapeutics (SRPT), which is developing its own treatment for DMD, is trading higher while PTC Therapeutics (PTCT) is moving lower. Reference Link
07:16 EDTGMEGameStop should be bought on any weakness after results, says Oppenheimer
Subscribe for More Information
November 19, 2015
14:49 EDTPTCTBefore the Move: Watch BioMarin into FDA advisory committee
BioMarin Pharmaceutical (BMRN), which develops and commercializes pharmaceuticals for serious diseases and medical conditions including Duchenne muscular dystrophy, or DMD, is awaiting an FDA advisory committee for its DMD drug drisapersen, which is brand named Kyndrisa. WHAT'S NEW: The Peripheral and Central Nervous System Drugs Advisory Committee is meeting on Tuesday, November 24 to discuss the New Drug Application, or NDA, for Biomarin's drisapersen. It is expected that briefing documents related to that meeting will be posted on the FDA's website tomorrow, Friday, November 20. BULLISH TAKE: On November 15, Leerink analyst Joseph Schwartz said he believes the FDA will feel compelled to approve at least one DMD drug due to "public attention and vocal demand," and says that most likely both drisapersen and Sarepta Therapeutics' (SRPT) eteplirsen will be approved. However, he also makes a case where eteplirsen is not approved due to the "extremely limited" clinical data on the drug. Schwartz noted that drisapersen's advisory panel on November 24 happens first and will be important for both companies, adding that he sees "significant" upside potential for BioMarin. On November 18, Goldman Sachs said it views the risk/reward in BioMarin as favorable, with the advisory committee as a key catalyst on the company's path to non-GAAP profitability. Goldman has a Buy rating on BioMarin shares. On November 19, Jefferies analyst Gena Wang wrote that a buy-side survey the firm conducted suggests positive expectations for BioMarin's advisory committee. Wang, who said the survey of 58 investors suggests buy-side expectations of a positive panel for Kyndrisa are 62%, noted that a positive outcome could push BioMarin higher by almost 20%, and positively impact peers PTC Therapeutics (PTCT) and Sarepta by over 20% and 6%, respectively. BAIRD CAUTIOUS: On November 19, Baird analyst Brian Skorney wrote a note titled "A Skeptic's Guide to DMD Regulatory Reviews" where he says the firm has "increasingly come to believe that the FDA is more likely to reject the NDA's for drisapersen and eteplirsen," although he notes the risk reward for BioMarin is skewed to the upside -- with 20% upside potential on approval, but only 10% downside potential on rejection. Baird has a Neutral rating on BioMarin. Skorney sees a 30% probability both drugs get approved during this review period, a 5% chance BioMarin's drug gets approved and Sarepta's gets rejected, a 5% chance Sarepta's gets approved and BioMarin's gets rejected, and a 60% chance that both get rejected. PRICE ACTION: In afternoon trading on Thursday, shares of BioMarin were down about 4.5% to $102.88, while shares of peers Sarepta and PTC Therapeutics were down 8% and 9.5%, respectively.
10:46 EDTPTCTOptions with increasing implied volatility
Options with increasing implied volatility: TERP PTCT CHK CSC GNC RH ULTA QCOM VIMC
09:00 EDTHPQ, ARUNAerohive sell-off unwarranted, says JMP Securities
Subscribe for More Information
08:07 EDTPTCTPTC Therapeutics completes enrollment of Phase 3 clinical trial of Translarna
PTC Therapeutics has completed enrollment of ACT CF, the company's second Phase 3 clinical trial of Translarna for patients with nonsense mutation cystic fibrosis. Nonsense mutations in cystic fibrosis are categorized as Class I mutations, which are the most difficult to treat, as they result in little or no production of the cystic fibrosis transmembrane conductance regulator protein. Approximately 10% of cystic fibrosis patients have their disease as a result of a nonsense mutation. On September 30, 2015, the EMA validated the submission of a variation for a new indication for Translarna for the treatment of nmCF.
07:23 EDTPTCTBuy-side sees 62% chance of positive BioMarin panel, says Jefferies
Jefferies analyst Gena Wang says her firm's survey of 58 investors suggests buy-side expectations of a positive FDA panel on November 24 for BioMarin's (BMRN) Kyndrisa are 62%. Both positive and negative outcomes are expected to result in significant moves for all three stocks developing treatments for Duchenne muscular dystrophy, or BioMarin, Sarepta (SRPT) and PTC Therapeutics (PTCT), Wang tells investors in a research note. Investors expect a positive Kyndrisa outcome to push BioMarin shares 19% higher, PTC shares 23% higher and Sarepta shares 6% higher, the analyst points out. She notes that a negative panel vote is expected to drive all three stocks 20%-30% lower.
November 17, 2015
10:20 EDTGMEOptions with increasing implied volatility
Options with increasing implied volatility: SGMS HZNP CSC ULTA RH BURL GME AEO BBRY TIF
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use